Klimov A I, Markushin S G, Prösch S, Ginzburg V P, Heider H, Heider A M, Schröeder C, Webster R G
Research Institute for Viral Preparations, Academy of Medical Sciences, Moscow, U.S.S.R.
Arch Virol. 1992;124(1-2):147-55. doi: 10.1007/BF01314632.
Norakin-resistant (NR) mutants of fowl plague virus (A/FPV/Weybridge, H7N7) have 1 to 2 (in one instance 3) amino acid substitutions in different positions of the heavy (HA 1) and/or light (HA 2) subunits of the haemagglutinin (HA) molecule. Investigation of NR mutants using the haemagglutination inhibition test with monoclonal antibodies (MAb) to the HA of A/seal/Massachusetts/80 (H7N7) virus revealed that one of the mutants (NR 1) differs antigenically from the wild-type fowl plague virus: its haemagglutination was not inhibited by MAb 55/2 and 58/6. By contrast, MAb-resistant (escape) mutants, selected from the wild-type fowl plague virus under pressure from MAb 55/2 or 58/6, showed reduced drug sensitivity. These findings suggest a possibility of correlation between alteration of influenza virus antigenicity and change of its sensitivity to drugs whose target is the haemagglutinin. This potential effect should be taken into account when antiviral substances directed to surface influenza virus antigens are being developed for use as antiviral drugs.
禽痘病毒(A/FPV/韦布里奇,H7N7)的诺拉金抗性(NR)突变体在血凝素(HA)分子的重链(HA 1)和/或轻链(HA 2)亚基的不同位置有1至2个(有一例为3个)氨基酸替换。使用针对A/海豹/马萨诸塞州/80(H7N7)病毒HA的单克隆抗体(MAb)通过血凝抑制试验对NR突变体进行研究发现,其中一个突变体(NR 1)在抗原性上与野生型禽痘病毒不同:其血凝反应未被MAb 55/2和58/6抑制。相比之下,在MAb 55/2或58/6的压力下从野生型禽痘病毒中筛选出的MAb抗性(逃逸)突变体显示出药物敏感性降低。这些发现提示了流感病毒抗原性改变与其对以血凝素为靶点的药物敏感性变化之间存在关联的可能性。在开发针对流感病毒表面抗原的抗病毒物质用作抗病毒药物时,应考虑到这种潜在影响。